<DOC>
	<DOCNO>NCT02515227</DOCNO>
	<brief_summary>This study evaluate whether safe administer peptide vaccine combination pembrolizumab . This study also evaluate effect combination peptide vaccine pembrolizumab immune system . The investigator monitor effect perform test laboratory participant ' blood , lymph node , tumor sample .</brief_summary>
	<brief_title>Safety Study Helper Peptide Vaccine Plus Pembrolizumab</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Ability provide write informed consent/assent trial . 2 . ≥18 year age 3 . A subject may naïve immunotherapy agent receive interferonalpha , ipilimumab CTLA4 antibody , PD1 antibody ( antiPDL1 antibody ) , interleukin2 , prior cancer vaccine 6MHP vaccine . Patients receive PD1/PDL1 antibody may enrol either follow setting : 1 . A patient experienced progression melanoma therapy complete therapy , 2 . A patient fail experience objective clinical response ( partial response complete response RECIST 1.1 criterion ) either 12 week continuous antiPD1 antibody antiCTLA4/antiPD1 combination therapy , candidate receive pembrolizumab therapy 4 . Measurable disease base RECIST 1.1 . Subjects require radiological study define radiologically evident disease . Required study include : Chest CT scan , Abdominal pelvic CT scan , Head CT scan MRI PET/CT fusion scan may replace scan chest , abdomen , pelvis . 5 . Subjects metastatic melanoma available biopsy pretreatment day 22 must consent biopsy . These metastasis may nod , skin , soft tissue , liver , site access safely needle biopsy , incisional excisional biopsy , without image guidance . The lesion biopsied must specify study enrollment include target lesion RECIST calculation . In instance disease accessible biopsy limit , archival tissue specimen collect subject 's last systemic therapy may use baseline measure . Subjects must measurable disease addition lesion ( ) biopsied . 6 . Subjects brain metastasis eligible follow true : Each brain metastasis must completely remove surgery unresected brain metastasis must treat stereotactic radiosurgery . There evident growth brain metastasis since recent treatment No brain metastasis &gt; 2 cm diameter time registration . Neurologic symptom return baseline , There evidence new enlarge brain metastasis , Subjects use steroid least 7 day prior registration . 7 . The recent surgical resection gammaknife therapy malignant melanoma must complete ≥ 1 week prior registration . 8 . ECOG performance status 0 1 9 . Adequate organ function . 10 . Two intact ( undissected ) axillary and/or inguinal lymph node basin . Exclusion Criteria 1 . Is currently participate participate study investigational agent use investigational device within 4 week first dose treatment . 2 . Is currently receive Interferon ( e.g . IntronA® ) , growth factor ( e.g . Procrit® , Aranesp® , Neulasta® ) , interleukin ( e.g . Proleukin® ) , receive agent within 4 week first dose treatment . 3 . Is currently receive nitrosureas receive therapy within precede 6 week first dose treatment . 4 . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment follow exception ( permit ) : replacement steroid dose patient adrenal pituitary insufficiency Intraarticular steroid injection Inhaled steroid ( e.g . : Advair® , Flovent® , Azmacort® ) low dos ( less 500 mcg fluticasone per day , equivalent ) Topical nasal corticosteroid Nonsteroidal antiinflammatory drug 5 . Has prior monoclonal antibody within 4 week prior study Day 1 recover ( i.e . ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . 6 . Has prior chemotherapy , target small molecule therapy , external beam radiation therapy within 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . Note : Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . Note : If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . 7 . Has know additional malignancy progress require active treatment . Exceptions include carcinoma situ breast ( DCIS LCIS ) , basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy . 8 . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . 9 . Has active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Exceptions criterion include : Subjects vitiligo depigmenting illness . Resolved childhood asthma/atopy Intermittent use bronchodilator local steroid injection Hypothyroidism stable hormone replacement Sjogren 's syndrome The presence laboratory evidence autoimmune disease ( e.g . positive ANA titer ) without symptom Mild arthritis require NSAID medication 10 . Has evidence interstitial lung disease active , noninfectious pneumonitis . 11 . Has active infection require systemic therapy . 12 . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 13 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . 14 . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . 15 . Is HIV positive evidence active Hepatitis C virus ( test do within 6 month study entry ) active Hepatitis B virus . 16 . Has receive live vaccine allergy desensitization injection within 30 day prior first dose trial treatment . 17 . Has know suspect allergy component vaccine . 18 . Has vaccinate previously synthetic peptide include protocol . 19 . Is classify accord New York Heart Association classification Class III IV heart disease ( Appendix 12.5 ) . 20 . Has uncontrolled diabetes , define HGBA1C &gt; 7.5 % . 21 . Has body weight &lt; 110 pound ( without clothes ) enrollment , due amount frequency blood drawn .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>peptide</keyword>
	<keyword>vaccine</keyword>
	<keyword>Montanide ISA-51</keyword>
	<keyword>pembrolizumab</keyword>
	<keyword>PD-1</keyword>
	<keyword>KEYTRUDA</keyword>
</DOC>